Paul Higham, an experienced manager, has joined Valo Therapeutics Ltd as chief executive to lead the company through a new financing round and help take its first oncolytic virus compound into the clinic. Mr Higham was previously CEO of Glycotope GmbH and before that, CEO of Immatics Biotechnologies – both involved in immuno-oncology. Earlier in his career, he was director of commercial development at Ark Therapeutics Group Plc with a specific focus on the production of adenovirus vectors for gene-based medicines.
Valo Therapeutics announced the appointment on 3 August 2020.
Copyright 2020 Evernow Publishing Ltd